

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Posaconazole Injection Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/26/2023  |
| 7.9     | 04/14/2025     | 22491-00024 | Date of first issue: 10/16/2014 |

### SECTION 1. IDENTIFICATION

Product name : Posaconazole Injection Formulation  
Other means of identification : No data available

#### Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc  
Address : 126 E. Lincoln Avenue  
Rahway, New Jersey U.S.A. 07065  
Telephone : 908-740-4000  
Emergency telephone : 1-908-423-6000  
E-mail address : EHSDATASTEWARD@merck.com

#### Recommended use of the chemical and restrictions on use


Recommended use : Pharmaceutical  
Restrictions on use : Not applicable

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the Hazardous Products Regulations

Skin sensitization : Category 1  
Reproductive toxicity : Category 2  
Specific target organ toxicity : Category 1 (Adrenal gland, Bone marrow, Kidney, Liver, Nervous system, Reproductive organs)  
- repeated exposure (Oral)

#### GHS label elements

Hazard pictograms : 

Signal Word : Danger

Hazard Statements : H317 May cause an allergic skin reaction.  
H361d Suspected of damaging the unborn child.  
H372 Causes damage to organs (Adrenal gland, Bone marrow, Kidney, Liver, Nervous system, Reproductive organs) through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P260 Do not breathe mist or vapors.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P272 Contaminated work clothing should not be allowed out of

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Posaconazole Injection Formulation

Version 7.9      Revision Date: 04/14/2025      SDS Number: 22491-00024      Date of last issue: 09/26/2023  
Date of first issue: 10/16/2014

the workplace.

P280 Wear protective gloves, protective clothing, eye protection and face protection.

### Response:

P302 + P352 IF ON SKIN: Wash with plenty of water.

P308 + P313 IF exposed or concerned: Get medical attention.

P333 + P313 If skin irritation or rash occurs: Get medical attention.

P362 + P364 Take off contaminated clothing and wash it before reuse.

### Storage:

P405 Store locked up.

### Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

### Other hazards

None known.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

| Chemical name  | Common Name/Synonym             | CAS-No.     | Concentration (% w/w) |
|--|---------------------------------|-------------|-----------------------|
| .beta.-Cyclodextrin, sulfobutyl ethers, sodium salts | Betadex Sulfobutyl Ether Sodium | 182410-00-0 | $\geq 30 - < 60$ *    |
| Posaconazole   | No data available               | 171228-49-2 | $\geq 1 - < 5$ *      |

\* Actual concentration or concentration range is withheld as a trade secret

## SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Posaconazole Injection Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/26/2023  |
| 7.9     | 04/14/2025     | 22491-00024 | Date of first issue: 10/16/2014 |

|   |   |  |
|---|---|--|
| Most important symptoms and effects, both acute and delayed | : | Get medical attention.<br>Rinse mouth thoroughly with water.<br>Diarrhea<br>Fever<br>Headache<br>Nausea<br>Vomiting<br>May cause an allergic skin reaction.<br>Suspected of damaging the unborn child.<br>Causes damage to organs through prolonged or repeated exposure if swallowed. |
| Protection of first-aiders                                  | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).  |
| Notes to physician  | : | Treat symptomatically and supportively.  |

### SECTION 5. FIRE-FIGHTING MEASURES

|  |   |   |
|--|---|---|
| Suitable extinguishing media                   | : | Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO <sub>2</sub> )<br>Dry chemical  |
| Unsuitable extinguishing media                 | : | None known.   |
| Specific hazards during fire fighting          | : | Exposure to combustion products may be a hazard to health.  |
| Hazardous combustion products                  | : | Carbon oxides<br>Sulfur oxides<br>Metal oxides  |
| Specific extinguishing methods                 | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.<br>Use water spray to cool unopened containers.<br>Remove undamaged containers from fire area if it is safe to do so.<br>Evacuate area. |
| Special protective equipment for fire-fighters | : | In the event of fire, wear self-contained breathing apparatus.<br>Use personal protective equipment.  |

### SECTION 6. ACCIDENTAL RELEASE MEASURES

|   |   |  |
|---|---|--|
| Personal precautions, protective equipment and emergency procedures | : | Use personal protective equipment.<br>Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).                     |
| Environmental precautions   | : | Avoid release to the environment.<br>Prevent further leakage or spillage if safe to do so.<br>Prevent spreading over a wide area (e.g., by containment or oil barriers). |

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Posaconazole Injection Formulation

Version 7.9      Revision Date: 04/14/2025      SDS Number: 22491-00024      Date of last issue: 09/26/2023  
Date of first issue: 10/16/2014

Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not get on skin or clothing.  
Do not breathe mist or vapors.  
Do not swallow.  
Avoid contact with eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

| Components   | CAS-No.     | Value type<br>(Form of exposure) | Control parameters / Permissible concentration | Basis    |
|--------------|-------------|----------------------------------|--|----------|
| Posaconazole | 171228-49-2 | TWA                              | 300 µg/m3 (OEB                                 | Internal |

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Posaconazole Injection Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/26/2023  |
| 7.9     | 04/14/2025     | 22491-00024 | Date of first issue: 10/16/2014 |

|  |  |  |    |  |
|--|--|--|----|--|
|  |  |  | 2) |  |
|--|--|--|----|--|

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Laboratory operations do not require special containment.

### Personal protective equipment

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Particulates type

**Hand protection** : Chemical-resistant gloves

**Material** : Chemical-resistant gloves

**Eye protection** : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat.

**Hygiene measures** : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Contaminated work clothing should not be allowed out of the workplace.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

**Appearance** : Aqueous solution

**Color** : Colorless to pale yellow

**Odor** : odorless

**Odor Threshold** : No data available

**pH** : 2.6

**Melting point/freezing point** : No data available

**Initial boiling point and boiling range** : No data available

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Posaconazole Injection Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/26/2023  |
| 7.9     | 04/14/2025     | 22491-00024 | Date of first issue: 10/16/2014 |

|  |   |  |
|--|---|--|
| Flash point                                      | : | No data available  |
| Evaporation rate                                 | : | No data available  |
| Flammability (solid, gas)                        | : | Not applicable   |
| Flammability (liquids)                           | : | No data available  |
| Upper explosion limit / Upper flammability limit | : | No data available  |
| Lower explosion limit / Lower flammability limit | : | No data available  |
| Vapor pressure                                   | : | No data available  |
| Relative vapor density                           | : | No data available  |
| Relative density                                 | : | No data available  |
| Density  | : | 1.15 g/cm <sup>3</sup>                                   |
| Solubility(ies)                                  |   |  |
| Water solubility                                 | : | No data available  |
| Partition coefficient: n-octanol/water           | : | Not applicable   |
| Autoignition temperature                         | : | No data available  |
| Decomposition temperature                        | : | No data available  |
| Viscosity  |   |  |
| Viscosity, kinematic                             | : | No data available  |
| Explosive properties                             | : | Not explosive  |
| Oxidizing properties                             | : | The substance or mixture is not classified as oxidizing. |
| Molecular weight                                 | : | No data available  |
| Particle characteristics                         |   |  |
| Particle size                                    | : | Not applicable   |

### SECTION 10. STABILITY AND REACTIVITY

|                                    |   |   |
|------------------------------------|---|---|
| Reactivity                         | : | Not classified as a reactivity hazard.  |
| Chemical stability                 | : | Stable under normal conditions.         |
| Possibility of hazardous reactions | : | Can react with strong oxidizing agents. |
| Conditions to avoid                | : | None known.                             |

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Posaconazole Injection Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/26/2023  |
| 7.9     | 04/14/2025     | 22491-00024 | Date of first issue: 10/16/2014 |

|                                  |   |  |
|----------------------------------|---|--|
| Incompatible materials           | : | Oxidizing agents                               |
| Hazardous decomposition products | : | No hazardous decomposition products are known. |

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

|                     |   |  |
|---------------------|---|--|
| Acute oral toxicity | : | Acute toxicity estimate: > 2,000 mg/kg |
|                     | : | Method: Calculation method             |

#### Components:

##### **.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:**

|                       |   |                              |
|-----------------------|---|------------------------------|
| Acute oral toxicity   | : | LD50 (Rat): > 2,000 mg/kg    |
| Acute dermal toxicity | : | LD50 (Rabbit): > 2,000 mg/kg |

##### **Posaconazole:**

|                       |   |                             |
|-----------------------|---|-----------------------------|
| Acute oral toxicity   | : | LD50 (Rat): > 5,000 mg/kg   |
|                       | : | LD50 (Mouse): > 3,000 mg/kg |
| Acute dermal toxicity | : | LD50 (Rat): > 2,000 mg/kg   |

#### Skin corrosion/irritation

Not classified based on available information.

#### Components:

##### **.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:**

|        |   |                    |
|--------|---|--------------------|
| Result | : | No skin irritation |
|--------|---|--------------------|

##### **Posaconazole:**

|         |   |                    |
|---------|---|--------------------|
| Species | : | Rabbit             |
| Result  | : | No skin irritation |

#### Serious eye damage/eye irritation

Not classified based on available information.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Posaconazole Injection Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/26/2023  |
| 7.9     | 04/14/2025     | 22491-00024 | Date of first issue: 10/16/2014 |

---

### Components:

#### **.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:**

Result : No eye irritation

#### **Posaconazole:**

Species : Rabbit  
Result : Mild eye irritation

### **Respiratory or skin sensitization**

#### **Skin sensitization**

May cause an allergic skin reaction.

#### **Respiratory sensitization**

Not classified based on available information.

### Components:

#### **.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:**

Assessment : Probability or evidence of skin sensitization in humans

#### **Posaconazole:**

Test Type : Magnusson-Kligman-Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Result : negative

### **Germ cell mutagenicity**

Not classified based on available information.

### Components:

#### **.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Method: OECD Test Guideline 476  
Result: negative  
Remarks: The test was conducted according to guideline

Test Type: Chromosome aberration test in vitro  
Result: negative

#### **Posaconazole:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosomal aberration  
Result: negative

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Posaconazole Injection Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/26/2023  |
| 7.9     | 04/14/2025     | 22491-00024 | Date of first issue: 10/16/2014 |

---

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Intravenous  
Result: negative

### Carcinogenicity

Not classified based on available information.

#### Components:

##### **Posaconazole:**

Species : Rat  
Application Route : oral (feed)  
Exposure time : 2 Years  
Result : positive  
Remarks : The mechanism or mode of action is not relevant in humans.

Species : Mouse  
Application Route : Oral  
Exposure time : 2 Years  
Result : positive  
Remarks : The mechanism or mode of action is not relevant in humans.

### Reproductive toxicity

Suspected of damaging the unborn child.

#### Components:

##### **Posaconazole:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male  
General Toxicity Parent: NOAEL: 180 mg/kg body weight  
Symptoms: No effects on mating performance.  
Result: negative

Test Type: Fertility/early embryonic development  
Species: Rat, female  
General Toxicity Parent: NOAEL: 45 mg/kg body weight  
Symptoms: No effects on mating performance.  
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat, female  
Application Route: Oral  
Developmental Toxicity: LOAEL: 29 mg/kg body weight  
Result: Fetotoxicity., Malformations were observed.

Test Type: Embryo-fetal development  
Species: Rabbit, female  
Developmental Toxicity: LOAEL: 40 mg/kg body weight  
Result: Fetotoxicity.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Posaconazole Injection Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/26/2023  |
| 7.9     | 04/14/2025     | 22491-00024 | Date of first issue: 10/16/2014 |

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

### STOT-single exposure

Not classified based on available information.

### STOT-repeated exposure

Causes damage to organs (Adrenal gland, Bone marrow, Kidney, Liver, Nervous system, Reproductive organs) through prolonged or repeated exposure if swallowed.

### Components:

#### Posaconazole:

|                    |  |
|--------------------|--|
| Routes of exposure | : Ingestion  |
| Target Organs      | : Adrenal gland, Bone marrow, Kidney, Liver, Reproductive organs, Nervous system |
| Assessment         | : Causes damage to organs through prolonged or repeated exposure.                |

### Repeated dose toxicity

### Components:

#### Posaconazole:

|                   |   |
|-------------------|---|
| Species           | : Rat, female   |
| LOAEL             | : 5 mg/kg   |
| Application Route | : Oral  |
| Exposure time     | : 6 Months  |
| Target Organs     | : Adrenal gland, Lungs, Heart, Liver, spleen, Kidney, Ovary |

|                   |   |
|-------------------|---|
| Species           | : Dog   |
| LOAEL             | : 3 mg/kg   |
| Application Route | : Oral  |
| Exposure time     | : 392 Days  |
| Target Organs     | : Lungs, Liver, Brain, small intestine, Adrenal gland, Spinal cord, lymphoid tissue |

|                   |  |
|-------------------|--|
| Species           | : Monkey   |
| LOAEL             | : 15 mg/kg                                       |
| Application Route | : Oral   |
| Exposure time     | : 1 Months                                       |
| Target Organs     | : Bone marrow, Adrenal gland, Lymph nodes, Blood |

|                   |   |
|-------------------|---|
| Species           | : Dog   |
| LOAEL             | : 3 mg/kg   |
| Application Route | : Oral  |
| Exposure time     | : 56 Weeks  |
| Target Organs     | : Adrenal gland, Bone marrow, Kidney, Nervous system, spleen, thymus gland, Testis, lymphoid tissue |

|                   |             |
|-------------------|-------------|
| Species           | : Monkey    |
| LOAEL             | : 180 mg/kg |
| Application Route | : Oral      |

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Posaconazole Injection Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/26/2023  |
| 7.9     | 04/14/2025     | 22491-00024 | Date of first issue: 10/16/2014 |

|                   |   |   |
|-------------------|---|---|
| Exposure time     | : | 12 Months   |
| Target Organs     | : | Blood, Gastrointestinal tract, spleen               |
| Species           | : | Monkey  |
| LOAEL             | : | 8 mg/kg   |
| Application Route | : | Intravenous   |
| Exposure time     | : | 1 Months  |
| Target Organs     | : | Cardio-vascular system, Lungs, Adrenal gland, Blood |

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

#### **Posaconazole:**

|           |   |   |
|-----------|---|---|
| Ingestion | : | Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver effects, Rash, pruritis, Diarrhea, hypertension, neutropenia, electrolyte imbalance |
|-----------|---|---|

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

#### **.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:**

|  |   |   |
|--|---|---|
| Toxicity to fish   | : | LC50 (Oncorhynchus mykiss (rainbow trout)): > 220 mg/l<br>Exposure time: 96 h   |
| Toxicity to daphnia and other aquatic invertebrates                    | : | EC50 (Daphnia magna (Water flea)): > 96 mg/l<br>Exposure time: 48 h   |
| Toxicity to algae/aquatic plants                                       | : | ErC50 (Selenastrum capricornutum (green algae)): > 100 mg/l<br>Exposure time: 72 h  |
| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) | : | NOEC (Daphnia magna (Water flea)): 100 mg/l<br>Exposure time: 21 d<br>Method: OECD Test Guideline 211<br>Remarks: The test was conducted according to guideline |
| Toxicity to microorganisms   | : | NOEC: 100 mg/l<br>Exposure time: 3 h  |

#### **Posaconazole:**

|   |   |   |
|---|---|---|
| Toxicity to fish                                    | : | LC50 (Oncorhynchus mykiss (rainbow trout)): > 0.95 mg/l<br>Exposure time: 96 h<br>Method: OECD Test Guideline 203<br>Remarks: No toxicity at the limit of solubility. |
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): 0.276 mg/l<br>Exposure time: 48 h  |

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Posaconazole Injection Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/26/2023  |
| 7.9     | 04/14/2025     | 22491-00024 | Date of first issue: 10/16/2014 |

Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.509 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.041 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.206 mg/l  
Exposure time: 33 d  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.244 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211  
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50 (Natural microorganism): > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

### Persistence and degradability

#### Components:

##### **.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 2 %  
Exposure time: 28 d

##### **Posaconazole:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 50 %  
Exposure time: 28 h  
Method: OECD Test Guideline 314

Stability in water : Degradation half life (DT50): > 30 d  
Method: OECD Test Guideline 111

### Bioaccumulative potential

#### Components:

##### **.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:**

Partition coefficient: n-octanol/water : log Pow: < -2

##### **Posaconazole:**

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Posaconazole Injection Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/26/2023  |
| 7.9     | 04/14/2025     | 22491-00024 | Date of first issue: 10/16/2014 |

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 20  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.15

### Mobility in soil

#### Components:

#### Posaconazole:

Distribution among environmental compartments : log Koc: 5.52

#### Other adverse effects

No data available

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

#### IMDG-Code

Not regulated as a dangerous good

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### Domestic regulation

#### TDG

Not regulated as a dangerous good

### Special precautions for user

Not applicable

## SECTION 15. REGULATORY INFORMATION

### The ingredients of this product are reported in the following inventories:

AICS : not determined

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Posaconazole Injection Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/26/2023  |
| 7.9     | 04/14/2025     | 22491-00024 | Date of first issue: 10/16/2014 |

DSL : not determined

IECSC : not determined

### SECTION 16. OTHER INFORMATION

#### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 04/14/2025  
Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Posaconazole Injection Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/26/2023  |
| 7.9     | 04/14/2025     | 22491-00024 | Date of first issue: 10/16/2014 |

---

guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8